Advertisement

Medical Oncology

, 34:155 | Cite as

Effect of a 12-week integrative oncology intervention on gastro-intestinal concerns in patients with gynecological and breast cancer undergoing chemotherapy

  • Ilanit Shalom-Sharabi
  • Lital Keinan-Boker
  • Noah Samuels
  • Ofer Lavie
  • Efraim Lev
  • Eran Ben-AryeEmail author
Short Communication

Abstract

Research on the long-term effects of complementary and integrative medicine (CIM) is limited. In this study, we explore the impact of a CIM intervention on gastro-intestinal (GI)-related concerns in patients with breast/gynecological cancer undergoing chemotherapy. Patients reporting chemotherapy-related GI concerns were referred by their cancer care providers to a CIM consultation and treatments and assessed at baseline and at 12 weeks. The following tools were used: Edmonton Symptom Assessment Scale (ESAS), Measure Yourself Concerns and Wellbeing (MYCAW) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). The intervention group was subdivided according to adherence to the integrative care program (AIC), defined as attending ≥4 CIM treatments with ≤30 days between each session. Controls chose not to undergo the CIM consultation or treatments. Of 289 patients reporting GI-related concerns, 42 were treated with CIM and optimally assessed (intervention arm; AIC = 33), as were 32 of controls. ESAS scores for appetite and nausea improved more significantly in the intervention group, more so in the AIC subgroup (appetite, p = 0.025; nausea, p = 0.033). MYCAW scores for GI-related concerns also improved in the intervention group, again more so in the adherent subgroup. EORTC scores improved more significantly with respect to global health (p = 0.021) and cognitive functioning (p = 0.031) in the intervention group, when compared to controls. The integration of a 12-week CIM intervention in conventional supportive cancer care may reduce nausea and improve appetite in patients with breast/gynecological cancer undergoing chemotherapy.

Keywords

Integrative medicine Breast cancer Complementary medicine Chemotherapy Appetite Nausea 

Notes

Acknowledgments

We would like to thank Ms. Ronit Leiba for her assistance in the statistical analysis of the data.

Author’s contribution

Ilanit Shalom-Sharabi, Dr. Noah Samuels and Prof. Eran Ben-Arye contributed to conception and design of the study, acquisition of the data, analysis and interpretation of the data, drafting the article and revising it critically for important content and final approval of the version to be submitted. Prof. Lital Keinan-Boker, Prof. Ofer Lavie and Prof. Efraim Lev helped in conception and design of the study, drafting the article and revising it critically for important content and final approval of the version to be submitted.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Human and animal rights statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Steinbach S, Hummel T, Böhner C, Berktold S, Hundt W, Kriner M, Heinrich P, Sommer H, Hanusch C, Prechtl A, Schmidt B, Bauerfeind I, Seck K, Jacobs VR, Schmalfeldt B, Harbeck N. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol. 2009;27(11):1899–905.CrossRefPubMedGoogle Scholar
  2. 2.
    Morita T, Fujimoto K, Namba M, Sasaki N, Ito T, Yamada C, Ohba A, Hiroyoshi M, Niwa H, Yamada T, Noda T. Palliative care needs of cancer outpatients receiving chemotherapy: an audit of a clinical screening project. Support Care Cancer. 2008;16(1):101–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Boltong A, Aranda S, Keast R, Wynne R, Francis PA, Chirgwin J, Gough K. A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes. PLoS ONE. 2014;9(7):e103512.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Efficace F, Biganzoli L, Piccart M, Coens C, Van Steen K, Cufer T, Coleman RE, Calvert HA, Gamucci T, Twelves C, Fargeot P, Bottomley A, EORTC-BCG-IDBBC-NDDG. Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer. 2004;40(7):1021–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Lee CK, Stockler MR, Coates AS, Gebski V, Lord SJ, Simes RJ, Australian New Zealand Breast Cancer Trials Group. Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer. 2010;102(9):1341–7.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002;20(2):567–73.CrossRefPubMedGoogle Scholar
  7. 7.
    Guo L, Bai SP, Zhao L, Wang XH. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol. 2012;29(3):1656–62.CrossRefPubMedGoogle Scholar
  8. 8.
    Kienle GS, Kiene H. Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther. 2010;9(2):142–57.CrossRefPubMedGoogle Scholar
  9. 9.
    Ben-Arye E, Aharonson ML, Schiff E, Samuels N. Alleviating gastro-intestinal symptoms and concerns by integrating patient-tailored complementary medicine in supportive cancer care. Clin Nutr. 2015;34(6):1215–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Shalom-Sharabi I, Samuels N, Lavie O, Lev E, Keinan-Boker L, Schiff E, Ben-Arye E. Effect of a patient-tailored integrative medicine program on gastro-intestinal concerns and quality of life in patients with breast and gynecologic cancer. J Cancer Res Clin Oncol. 2017;143(7):1243–54.CrossRefGoogle Scholar
  11. 11.
    Bruera E, Kuehn N, Miller M, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7(2):6–9.PubMedGoogle Scholar
  12. 12.
    Paterson C, Thomas K, Manasse A, Cooke H, Peace G. Measure Yourself Concerns and Wellbeing (MYCaW): an individualised questionnaire for evaluating outcome in cancer support care that includes complementary therapies. Complement Ther Med. 2007;15(1):38–45.CrossRefPubMedGoogle Scholar
  13. 13.
    Aaronson N, Ahmedzai S, Bergman B, Bullinger M, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Sharabi IS, Levin A, Schiff E, Samuels N, Agour O, Tapiro Y, Lev E, Keinan-Boker L, Ben-Arye E. Quality of life-related outcomes from a patient-tailored integrative medicine program: experience of Russian-speaking patients with cancer in Israel. Support Care Cancer. 2016;24(10):4345–55.CrossRefGoogle Scholar
  15. 15.
    Ben-Arye E, Samuels N, Schiff E, Raz OG, Sharabi IS, Lavie O. Quality-of-life outcomes in patients with gynecologic cancer referred to integrative oncology treatment during chemotherapy. Support Care Cancer. 2015;23(12):3411–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Mao H, Mao JJ, Guo M, Cheng K, Wei J, Shen X, Shen X. Effects of infrared laser moxibustion on cancer-related fatigue: a randomized, double-blind, placebo-controlled trial. Cancer. 2016;122(23):3667–72.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Song QH, Xu RM, Zhang QH, Ma M, Zhao XP. Relaxation training during chemotherapy for breast cancer improves mental health and lessens adverse events. Int J Clin Exp Med. 2013;6(10):979–84.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Mustian KM, Sprod LK, Janelsins M, Peppone LJ, Palesh OG, Chandwani K, Reddy PS, Melnik MK, Heckler C, Morrow GR. Multicenter, randomized controlled trial of yoga for sleep quality among cancer survivors. J Clin Oncol. 2013;31(26):3233–4.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Integrative Oncology Program, The Oncology Service, Lin Medical CenterClalit Health Services, Haifa and Western Galilee DistrictHafiaIsrael
  2. 2.The Graduate Studies AuthorityUniversity of HaifaHaifaIsrael
  3. 3.School of Public Health, Faculty of Social Welfare and Health SciencesUniversity of HaifaHaifaIsrael
  4. 4.Israel Center for Disease ControlIsrael Ministry of HealthRamat GanIsrael
  5. 5.Tal Center for Integrative Oncology, Institute of OncologySheba Medical CenterTel HashomerIsrael
  6. 6.Department of Obstetrics and Gynecology, Gynecologic Oncology ServiceCarmel Medical CenterHaifaIsrael
  7. 7.Department of Israel StudiesUniversity of HaifaHaifaIsrael
  8. 8.Complementary and Traditional Medicine Unit, Department of Family Medicine, Faculty of MedicineTechnion-Israel Institute of TechnologyHaifaIsrael

Personalised recommendations